Progenity Inc. (NASDAQ: PROG) has announced that it has received another patent for its single-molecule detection assay platform that is undergoing development,
Progenity receives patent for single-molecule detection platform
The United States Patent and Trademark Office issued Patent No. 11,230,731 is entitled “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” It covers claims related to detecting a tagged target particle on a solid support.
General Manager Diagnostics Matthew Cooper stated, “We have added another important patent to our IP portfolio for the single-molecule detection platform, which is designed to enable sequence-free counting of target analytes including cell-free nucleic acids. We believe this approach may have important near-term impact in the fields of noninvasive prenatal testing (NIPT) and liquid biopsy.”
This newest patent covers crucial formulations and tagging procedures for target molecules. The platform can potentially lower genetic test operating costs and turnaround times drastically, with applications ranging from proteins to nucleic acids. The company is committed to optimizing the value of its patent portfolio and is seeking collaborations and other options that could help us get to market faster.
Sing-molecule platform supported by six patent families
The company’s single-molecule recognition platform is supported by a patent portfolio that includes six patent groups covering various aspects of the single-molecule counting platform and a different family dedicated to identifying nucleosomal placement patterns, like cell-free DNA tissue-of-origin evaluation. The patents are part of the company’s patent portfolio, which includes 96 patent families, 180 granted patents, and over 220 pending submissions. The portfolio comprises patents and patent applications for medication administration methods and devices, GI sampling devices and diagnostics methods, illness treatment methods and compositions, and genetic and protein tools, assays, and diagnostics.
Progenity’s molecular testing tools and the creation of a portfolio of experimental ingestible devices meant to offer accurate diagnostic samples, and medication delivery solutions use a multi-omics approach, incorporating genomes, proteomics, epigenomics, and metabolomics. The company’s mission is to make healthcare more accurate and personalized by enhancing disease diagnostics and increasing health outcomes through tailored medicines delivered locally.
